文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

代谢相关脂肪性肝病(MASLD)防治的健康功能性食品生物标志物:网络药理学、肠道微生物群和多组学的综合分析

Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics.

机构信息

Department of Bioconvergence, Hoseo University, Asan 31499, Republic of Korea.

Clinical Trial Center for Functional Foods, Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju 54907, Republic of Korea.

出版信息

Nutrients. 2024 Sep 11;16(18):3061. doi: 10.3390/nu16183061.


DOI:10.3390/nu16183061
PMID:39339660
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11434757/
Abstract

Metabolic dysfunction-associated steatotic liver disorder (MASLD) is increasingly prevalent globally, highlighting the need for preventive strategies and early interventions. This comprehensive review explores the potential of health functional foods (HFFs) to maintain healthy liver function and prevent MASLD through an integrative analysis of network pharmacology, gut microbiota, and multi-omics approaches. We first examined the biomarkers associated with MASLD, emphasizing the complex interplay of genetic, environmental, and lifestyle factors. We then applied network pharmacology to identify food components with potential beneficial effects on liver health and metabolic function, elucidating their action mechanisms. This review identifies and evaluates strategies for halting or reversing the development of steatotic liver disease in the early stages, as well as biomarkers that can evaluate the success or failure of such strategies. The crucial role of the gut microbiota and its metabolites for MASLD prevention and metabolic homeostasis is discussed. We also cover state-of-the-art omics approaches, including transcriptomics, metabolomics, and integrated multi-omics analyses, in research on preventing MASLD. These advanced technologies provide deeper insights into physiological mechanisms and potential biomarkers for HFF development. The review concludes by proposing an integrated approach for developing HFFs targeting MASLD prevention, considering the Korean regulatory framework. We outline future research directions that bridge the gap between basic science and practical applications in health functional food development. This narrative review provides a foundation for researchers and food industry professionals interested in developing HFFs to support liver health. Emphasis is placed on maintaining metabolic balance and focusing on prevention and early-stage intervention strategies.

摘要

代谢相关脂肪性肝病(MASLD)在全球范围内日益普遍,凸显了预防策略和早期干预的必要性。本综述通过网络药理学、肠道微生物组和多组学方法的综合分析,探讨了健康功能性食品(HFF)在维持肝脏健康和预防 MASLD 方面的潜力。我们首先检查了与 MASLD 相关的生物标志物,强调了遗传、环境和生活方式因素的复杂相互作用。然后,我们应用网络药理学来识别对肝脏健康和代谢功能具有潜在有益作用的食物成分,阐明其作用机制。本综述确定并评估了在早期阶段阻止或逆转脂肪性肝病发展的策略,以及可评估此类策略成败的生物标志物。讨论了肠道微生物组及其代谢产物在预防 MASLD 和代谢平衡中的关键作用。我们还涵盖了转录组学、代谢组学和综合多组学分析等最先进的组学方法在预防 MASLD 研究中的应用。这些先进技术为 HFF 开发提供了对生理机制和潜在生物标志物的更深入了解。本综述最后提出了一种针对 MASLD 预防的 HFF 开发的综合方法,同时考虑了韩国的监管框架。我们概述了未来的研究方向,旨在弥合基础科学与健康功能性食品开发实际应用之间的差距。本综述为有兴趣开发 HFF 以支持肝脏健康的研究人员和食品行业专业人员提供了基础。重点是维持代谢平衡,并关注预防和早期干预策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbfa/11434757/a3d7e8efe3a3/nutrients-16-03061-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbfa/11434757/33bcfd123b39/nutrients-16-03061-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbfa/11434757/f14cf8670d41/nutrients-16-03061-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbfa/11434757/a3d7e8efe3a3/nutrients-16-03061-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbfa/11434757/33bcfd123b39/nutrients-16-03061-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbfa/11434757/f14cf8670d41/nutrients-16-03061-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbfa/11434757/a3d7e8efe3a3/nutrients-16-03061-g003.jpg

相似文献

[1]
Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics.

Nutrients. 2024-9-11

[2]
Exploring the Regulatory Effect of LPJZ-658 on Copper Deficiency Combined with Sugar-Induced MASLD in Middle-Aged Mice Based on Multi-Omics Analysis.

Nutrients. 2024-6-25

[3]
Gut microbiota-NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease.

Clin Res Hepatol Gastroenterol. 2024-10

[4]
Integrated bioinformatics and multiomics reveal Liupao tea extract alleviating NAFLD via regulating hepatic lipid metabolism and gut microbiota.

Phytomedicine. 2024-9

[5]
Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.

Sci Rep. 2024-7-12

[6]
Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Nutrients. 2024-5-29

[7]
Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.

Gut Microbes. 2024

[8]
Hepatic Steatosis Can Be Partly Generated by the Gut Microbiota-Mitochondria Axis via 2-Oleoyl Glycerol and Reversed by a Combination of Soy Protein, Chia Oil, Curcumin and Nopal.

Nutrients. 2024-8-6

[9]
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.

Curr Obes Rep. 2024-9

[10]
Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease.

Hepatol Commun. 2024-3-1

引用本文的文献

[1]
Enterotype-stratified gut microbial signatures in MASLD and cirrhosis based on integrated microbiome data.

Front Microbiol. 2025-5-15

[2]
Association of the newly proposed dietary index for gut microbiota and hyperlipidemia: From the 2007-2020 NHANES study.

PLoS One. 2025-5-19

[3]
Changes in Liver Metabolome Induced by Pterostilbene and Resveratrol in a Rat Model of Liver Steatosis.

Mol Nutr Food Res. 2025-8

[4]
A robust diagnostic model for high-risk MASH: integrating clinical parameters and circulating biomarkers through a multi-omics approach.

Hepatol Int. 2025-4-9

[5]
Pollutants in Microenvironmental Cellular Interactions During Liver Inflammation Cancer Transition and the Application of Multi-Omics Analysis.

Toxics. 2025-2-25

[6]
Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.

Int J Mol Sci. 2025-2-13

[7]
Lipids dysregulation in diseases: core concepts, targets and treatment strategies.

Lipids Health Dis. 2025-2-21

[8]
Editorial: Precision nutrition and nutrients: making the promise a reality.

Front Nutr. 2025-1-27

[9]
Sex-Dependent Gut Microbiota Features and Functional Signatures in Metabolic Disfunction-Associated Steatotic Liver Disease.

Nutrients. 2024-12-4

[10]
Special Issue: "Gut Microbiota and Nutrition in Human Health".

Int J Mol Sci. 2024-10-29

本文引用的文献

[1]
Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future.

Transl Gastroenterol Hepatol. 2024-6-24

[2]
Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies.

Biomedicines. 2024-6-24

[3]
Induction of steatosis in primary human hepatocytes recapitulates key pathophysiological aspects of metabolic dysfunction-associated steatotic liver disease.

J Hepatol. 2025-1

[4]
Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment.

Hepatol Commun. 2024-7-1

[5]
Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.

Gut. 2024-12-10

[6]
A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions.

Front Med (Lausanne). 2024-6-4

[7]
The Role of _rs738409 Gene Variant, Lifestyle Factors, and Bioactive Compounds in Nonalcoholic Fatty Liver Disease: A Population-Based and Molecular Approach towards Healthy Nutrition.

Nutrients. 2024-4-21

[8]
Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective.

Metabolites. 2024-4-12

[9]
An adipocentric perspective of pancreatic lipotoxicity in diabetes pathogenesis.

J Endocrinol. 2024-7-1

[10]
Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).

Gut Microbes. 2024

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索